GH · Guardant Health, Inc.

Current Thesis

Guardant Health’s renewed advance prices broader Shield insurance coverage becoming screening revenue; the next quarterly screening result must exceed Q2’s $52.9 million, while a weekly close below $161.41 would invalidate the September extension. The revenue benchmark comes from the company’s 2026-07-30 results; the price threshold is the market’s 2026-09-04 reference close, selected here as a research condition. Q2 results.

The material change since the September 6 note is another payer announcement. On 2026-09-14, Guardant said EviCore coverage would become effective on 2027-01-01, bringing its stated Shield coverage reach to approximately 94 million people aged 45 and older. That figure describes announced coverage reach, including a future effective date; it does not measure completed tests or collected reimbursement. Company announcement.

The inference is that the narrative is accelerating — the 2026-09-14 coverage announcement and the 2026-09-18 close of $179.38 supersede the earlier description of stalled price momentum at $161.41 on 2026-09-04. UBS’s 2026-09-09 price target of $225 also contradicts the prior claim that analyst targets had stopped expanding. These observations establish renewed attention and a higher price, without establishing broader investor participation. Analyst target history.

Bullish and bearish views on Guardant Health, Inc.

The model's bull view on Guardant Health, Inc. (GH), in brief: Coverage expansion has another date. Guardant’s 2026-09-14 announcement adds EviCore coverage effective 2027-01-01. The conversion case would weaken if implementation were delayed or subsequent screening revenue failed to exceed the Q2 benchmark. Company announcement. Screening… The bear view: Policy announcements precede implementation. Both cases follow in full.

Bull Case

• Coverage expansion has another date. Guardant’s 2026-09-14 announcement adds EviCore coverage effective 2027-01-01. The conversion case would weaken if implementation were delayed or subsequent screening revenue failed to exceed the Q2 benchmark. Company announcement.
• Screening already produces measurable revenue. The 2026-07-30 release reported Q2 screening revenue of $52.9 million and approximately 66,000 Shield tests. These are operating measurements against which subsequent coverage announcements can be tested. Q2 results.
• Analyst attention expanded in September. Rothschild & Co initiated coverage with a $203 price target on 2026-09-08; UBS published a $225 target on 2026-09-09. These are third-party valuations, not evidence that reimbursement has converted into revenue. Analyst target history.

Bear Case

• Policy announcements precede implementation. Carelon’s 2026-09-01 announcement specified a 2026-11-15 effective date; EviCore’s 2026-09-14 release specified 2027-01-01. Neither effective date falls within Q3 2026, so that quarter cannot establish conversion under those newly effective policies. EviCore announcement.
• Litigation remains unresolved on appeal. The 2026-08-24 judgment described in the prior published record exceeded $245.2 million and included a 6% ongoing royalty on covered products. Guardant’s same-day announcement said execution and royalty collection were stayed pending appeal; its assertions about product exclusions remain company statements. An adverse appellate ruling or broader royalty exposure would undermine the revenue-conversion case. Company appeal statement.
• The price advance precedes confirmation. Adjusted daily bars dated 2026-09-18 show a three-month price increase of 39.2%, with the close 2.0% below the supplied 52-week high. A return below the September reference threshold before a stronger screening result would invalidate this continuation thesis.

Setup & Price Structure

The measured 2026-09-18 close is $179.38, against a supplied 52-week high of $183.10. The 14-period relative strength index, a momentum measure, is 67.8. These observations describe elevated momentum near the high; they do not establish a completed breakout.

A weekly close above $183.10 would confirm passage through the supplied high. A weekly close below $161.41 would erase the September extension relative to the 2026-09-04 reference close. The latter is an explicitly selected thesis threshold, not a moving average or a claim that repeated support tests occurred there.

The observable attention cluster comprises Rothschild’s 2026-09-08 initiation, UBS’s 2026-09-09 target and the 2026-09-15 Morgan Stanley appearance. No verified moving-average distance, short-interest series or retail-flow sample is available here; the evidence does not support a crowding verdict. Analyst history, conference announcement.

Catalyst Calendar (next 30 days)

For 2026-09-20 through 2026-10-20, no company-confirmed catalyst date was verifiable from the accessible investor calendar. The 2026-09-15 conference is elapsed, and the accessible transcript does not expose enough substantive remarks to determine whether management supplied a new volume or reimbursement datapoint. No confirmed Q3 reporting date is established. Investor calendar, September 15 transcript listing.

• 2026-11-15 — Carelon coverage implementation. The effective date specified in Guardant’s 2026-09-01 announcement is the next established implementation milestone for the conversion thesis; a delay would weaken it.
• 2027-01-01 — EviCore coverage implementation. The date specified in the 2026-09-14 release separates announced reach from effective eligibility under that policy. A delay would invalidate the assumed implementation timetable. Company announcement.

What Would Change Our Mind

Loss of the September advance would break the price component: a weekly close below $161.41, the 2026-09-04 reference close, invalidates this extension thesis. That threshold tests the refreshed September case rather than asserting that Guardant’s products have failed commercially.

The operating confirmation is the next reported quarterly screening revenue exceeding Q2’s $52.9 million, as disclosed on 2026-07-30. A result at or below that benchmark would fail the stated acceleration test. Stronger screening revenue accompanied by implementation of the announced coverage policies would support the conversion interpretation; the price condition remains independently gradeable.

Correlation Notes

This is a single-name payer-conversion case. The dated evidence is Guardant-specific: EviCore’s 2026-09-14 policy announcement and GH’s 2026-09-18 adjusted close. No matched peer-return series is available to establish that diagnostics stocks moved together, and analyst coverage clustering cannot substitute for that measurement. No sector-correlation conclusion is supported by this sample.